Evidence map›Paper›PMID 32664939›Full record

ArticleMalaria journal2020

Mass testing and treatment for malaria followed by weekly fever screening, testing and treatment in Northern Senegal: feasibility, cost and impact.

Ruben O Conner, Yakou Dieye, Michael Hainsworth, Adama Tall, Badara Cissé, Farba Faye, Mame Demba Sy, Amadou Ba, Doudou Sene, Souleymane Ba and 10 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Evaluation of the Efficacy of FludoraTropical medicine and infectious disease · 2022
    Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 3 countries.

Ruben O ConnerPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Yakou DieyePATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Michael HainsworthPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Adama TallPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Badara CisséPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Farba FayePATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Mame Demba SyProgramme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.
Amadou BaPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Doudou SeneProgramme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.
Souleymane BaProgramme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.
Elhadji DoucouréProgramme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.
Tidiane ThiamProgramme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.
Moussa DiopPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Kammerle SchneiderPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Moustapha CisséProgramme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.
Mady BaProgramme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.
Duncan EarlePATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Philippe GuinotPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Richard W SteketeePATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Caterina GuinovartPATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA. cguinovart@path.org.ORCID http://orcid.org/0000-0003-0504-4486
Program for Appropriate Technology in Health · USMinistère de la Santé Publique et Action Sociale · SN

Funding

Bill & Melinda Gates Foundation OPP1148921
6 · The paper itself

Abstract

backgroundPopulation-wide interventions using malaria testing and treatment might decrease the reservoir of Plasmodium falciparum infection and accelerate towards elimination. Questions remain about their effectiveness and evidence from different transmission settings is needed.

methodsA pilot quasi-experimental study to evaluate a package of population-wide test and treat interventions was conducted in six health facility catchment areas (HFCA) in the districts of Kanel, Linguère, and Ranérou (Senegal). Seven adjacent HFCAs were selected as comparison. Villages within the intervention HFCAs were stratified according to the 2013 incidences of passively detected malaria cases, and those with an incidence ≥ 15 cases/1000/year were targeted for a mass test and treat (MTAT) in September 2014. All households were visited, all consenting individuals were tested with a rapid diagnostic test (RDT), and, if positive, treated with dihydroartemisinin-piperaquine. This was followed by weekly screening, testing and treatment of fever cases (PECADOM++) until the end of the transmission season in January 2015. Villages with lower incidence received only PECADOM++ or case investigation. To evaluate the impact of the interventions over that transmission season, the incidence of passively detected, RDT-confirmed malaria cases was compared between the intervention and comparison groups with a difference-in-difference analysis using negative binomial regression with random effects on HFCA.

resultsDuring MTAT, 89% (2225/2503) of households were visited and 86% (18,992/22,170) of individuals were tested, for a combined 77% effective coverage. Among those tested, 291 (1.5%) were RDT positive (range 0-10.8 by village), of whom 82% were < 20 years old and 70% were afebrile. During the PECADOM++ 40,002 visits were conducted to find 2784 individuals reporting fever, with an RDT positivity of 6.5% (170/2612). The combination of interventions resulted in an estimated 38% larger decrease in malaria case incidence in the intervention compared to the comparison group (adjusted incidence risk ratio = 0.62, 95% CI 0.45-0.84, p = 0.002). The cost of the MTAT was $14.3 per person.

conclusionsIt was operationally feasible to conduct MTAT and PECADOM++ with high coverage, although PECADOM++ was not an efficient strategy to complement MTAT. The modest impact of the intervention package suggests a need for alternative or complementary strategies.

Indexed as

AdolescentAdultAgedAntimalarialsArtemisininsChildChild, PreschoolDiagnostic Tests, RoutineFeasibility StudiesFemaleFeverHumansInfantMalaria, FalciparumMaleMass ScreeningAntimalarialsArtemisininsartenimolpiperaquinePiperazinesQuinolinesMalaria eliminationPlasmodium falciparumPopulation-wide interventionsTesting and treatment

Identifiers

PMID32664939
PMCPMC7362450
OpenAlexW3042589863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.